Attempt to revive HBV patent thwarted

Organisation: Position: Deadline Date: Location:

The US Supreme Court has brought to an end Bristol-Myers Squibb Co’s attempt to revive patent protection for its Baraclude treatment for hepatitis B (HBV). The high court declined to hear Bristol-Myers’ challenge to an appeals court ruling in favour of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent.

In a June 2014 ruling, the US Court of Appeals for the Federal Circuit upheld a federal district court’s finding that the patent was invalid. Teva announced last September that it was launching its generic version of the drug.

Meanwhile, The Independent reports that a drug for treating hepatitis B patients could be mass produced at a cost of only £24 per person per year according to a new piece of research from the University of Liverpool.

Full Reuters Health reportFull The Independent report


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.